Hyperfibrinogenemia increases the risk of cardiac events after coronary artery stenting |
| |
Authors: | A. Germing S. von Dryander Abderrahman Machraoui Waldemar Bojara Thomas Lawo Peter Grewe Jürgen Barmeyer Bernd Lemke |
| |
Affiliation: | (1) Department of Cardiology and Angiology, Berufsgenossenschaftliche Kliniken Bergmannsheil, University of Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany Fax +49-234-302-6084 e-mail: alfried.germing@ruhr-uni-bochum.de, DE;(2) Department of Internal Medicine, DIAKO, Flensburg, Germany, DE |
| |
Abstract: | Primary success rates, and the angiographic and clinical outcome after percutaneous coronary intervention, are influenced by many different factors. Clinical features and morphologic characteristics of the target lesion are important. Also, interventionally caused endothelial trauma may trigger atherogenetic and procoagulatory factors leading to intraluminal thrombosis. The study population consisted of 228 consecutive, unselected patients with symptomatic coronary artery disease or exercise-induced myocardial ischemia and coronary artery stenoses eligible for percutaneous intervention. We analyzed different clinical, morphological, and laboratory (total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglycerides, fibrinogen) features in those patients with adverse cardiac events (stent thrombosis, myocardial infarction, urgent target vessel revascularization, death) after primary successful coronary artery stenting, compared with a control group without adverse events. In the group with adverse cardiac events we found a significantly higher level of fibrinogen compared with the control group. Other laboratory data and clinical characteristics were not significantly different between the two groups. The study shows a possible association between hyperfibrinogenemia and adverse cardiac events after intracoronary stenting. In clinical practice, the potential role of elevated levels of fibrinogen in an unfavorable outcome after percutaneous coronary interventions should be considered when planning coronary artery stenting. Received: November 24, 2000 / Accepted: May 11, 2001 |
| |
Keywords: | Fibrinogen Coronary artery stenting Adverse cardiac events |
本文献已被 SpringerLink 等数据库收录! |
|